Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2023 Mar 13

PMID 36911254

Authors

Anat Fisher

Jason D Kim

Colin R Dormuth

Affiliations

Soon will be listed here.

Abstract

Background: On September 5, 2019, British Columbia announced a new policy (the Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases.

Objective: To monitor the impacts of the policy on the use of medications and health services during the first year of the policy.

Methods: In this population-based cohort study, we used administrative health data to construct three historical cohorts and one policy cohort of patients with inflammatory bowel diseases who used the originator infliximab. We then monitored the cumulative incidence of medications and health services. Log-likelihood ratios were used to quantify differences between the policy cohort and the average of the historical cohorts.

Results: The cohorts included 1839-2368 users of the originator infliximab, ages 4-90 years, mean age 43 years. During the first year of follow-up, we found: (1) a 0.9% increase in the first dispensation of infliximab, biosimilar, or originator; (2) a 16.2% increase in infliximab dose escalation; (3) a decrease of 2.4% in the dispensation of antibiotics and a 2.6% decrease in new use of prednison; (4) an anticipated increase in visits to physicians and gastroenterologists to manage switching to biosimilars (24.0%); (5) a 4.0% decrease in discharges from hospital; and (6) a 2.9% decrease in emergency admissions to hospital.

Conclusion: British Columbia's Biosimilars Initiative for nonmedical switching from originator to biosimilar infliximab for inflammatory bowel diseases was not associated with harmful impacts on medications and health services use. An increase in dose escalation was accompanied by an improvement in health status proxies.

Citing Articles

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data.

Birck M, Lukusa L, Choquette D, Boire G, Maksymowych W, Singh H BMC Rheumatol. 2024; 8(1):47.

PMID: 39343928 PMC: 11441163. DOI: 10.1186/s41927-024-00415-5.

References

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A . Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. Ther Drug Monit. 2019; 41(3):317-324. DOI: 10.1097/FTD.0000000000000601. View

Hughes A, Marshall J, Moretti M, Ungar W . A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. J Can Assoc Gastroenterol. 2021; 4(1):48. PMC: 7898373. DOI: 10.1093/jcag/gwz045. View

Convertino I, Lucenteforte E, Gini R, Lorenzoni V, Cazzato M, Turchetti G . Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons. Clin Exp Rheumatol. 2020; 39(4):753-762. View

Karlsson P, Nakitanda A, Lofling L, Cesta C . Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic. PLoS One. 2021; 16(8):e0253944. PMC: 8362980. DOI: 10.1371/journal.pone.0253944. View

Moayyedi P, Benchimol E, Armstrong D, Yuan C, Fernandes A, Leontiadis G . Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. J Can Assoc Gastroenterol. 2020; 3(1):e1-e9. PMC: 6985688. DOI: 10.1093/jcag/gwz035. View

Elbeddini A, Hooda N, Yang L . Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic. Can Pharm J (Ott). 2020; 153(4):198-203. PMC: 7605066. DOI: 10.1177/1715163520929387. View

Al Zoubi S, Gharaibeh L, Jaber H, Al-Zoubi Z . Household Drug Stockpiling and Panic Buying of Drugs During the COVID-19 Pandemic: A Study From Jordan. Front Pharmacol. 2022; 12:813405. PMC: 8730317. DOI: 10.3389/fphar.2021.813405. View

Fisher A, Kim J, Carney G, Dormuth C . Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia. BMC Rheumatol. 2022; 6(1):5. PMC: 8793256. DOI: 10.1186/s41927-021-00235-x. View

Liu Y, Yang M, Garg V, Wu E, Wang J, Skup M . Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review. Adv Ther. 2019; 36(8):1851-1877. PMC: 6822838. DOI: 10.1007/s12325-019-00998-3. View

10.

Fisher A, Kim J, Dormuth C . Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report. Pharmacoepidemiol Drug Saf. 2020; 29(7):803-810. DOI: 10.1002/pds.5008. View

11.

Hoivik M, Buer L, Cvancarova M, Warren D, Bolstad N, Moum B . Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018; 53(6):692-699. DOI: 10.1080/00365521.2018.1463391. View

12.

Click B, Lopez R, Arrigain S, Schold J, Regueiro M, Rizk M . Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 26(8):1268-1275. DOI: 10.1093/ibd/izz256. View

13.

Bhat S, Altajar S, Shankar D, Zahorian T, Robert R, Qazi T . Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb. J Manag Care Spec Pharm. 2020; 26(4):410-416. PMC: 10390955. DOI: 10.18553/jmcp.2020.26.4.410. View

14.

Limdi J, Farraye F . The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics. Crohns Colitis 360. 2023; 3(3):otab015. PMC: 9802304. DOI: 10.1093/crocol/otab015. View

15.

Park K, Ehrlich O, Allen J, Meadows P, Szigethy E, Henrichsen K . The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2019; 26(1):1-10. PMC: 7534391. DOI: 10.1093/ibd/izz104. View

16.

Ma C, Moran G, Benchimol E, Targownik L, Heitman S, Hubbard J . Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. Am J Gastroenterol. 2017; 112(12):1840-1848. PMC: 5729339. DOI: 10.1038/ajg.2017.394. View

17.

Bernard E, Fedorak R, Jairath V . Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci. 2020; 65(8):2354-2372. PMC: 7369127. DOI: 10.1007/s10620-019-06036-0. View

18.

Dormuth C, Fisher A, Carney G . A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia. Pharmacoepidemiol Drug Saf. 2020; 29(7):796-802. DOI: 10.1002/pds.4957. View

19.

Luber R, ONeill R, Singh S, Sharma E, Cunningham G, Honap S . An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther. 2021; 54(5):678-688. DOI: 10.1111/apt.16497. View

20.

Haifer C, Srinivasan A, An Y, Picardo S, Van Langenberg D, Menon S . Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Med J Aust. 2020; 214(3):128-133. DOI: 10.5694/mja2.50824. View